Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
78°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
205.00
+1.68 (+0.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
Next >
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm
February 09, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Biogen Shareholder Alert
February 09, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
CORRECTING and REPLACING Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
February 09, 2022
From
Robbins LLP
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors Biogen, Inc. (BIIB) is Being Sued for Misleading Shareholders
February 09, 2022
From
Robbins LLP
Via
Business Wire
Biogen Leads From the Top With Disability Inclusion
December 03, 2021
SOURCE: Biogen
Via
3BL Media
Biogen Deadline Alert
February 08, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
December 08, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
December 01, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
From Pause to Pride: A Mother's Journey
December 01, 2021
SOURCE: Biogen
Via
3BL Media
Topics
LGBTQ
Exposures
Diversity
Introducing Biogen's 2021 Diversity, Equity & Inclusion Report
November 04, 2021
SOURCE: Biogen
Via
3BL Media
MSM Students to Participate in Biogen's Summer Health Equity Fellowship Program
October 26, 2021
SOURCE: Biogen
Via
3BL Media
Youth Neurology Program: Building a More Diverse Neurology Workforce
November 30, 2021
SOURCE: Biogen
Via
3BL Media
Exposures
COVID-19
Wanda Castro-Borrero: Carrying on Legacy of Care
November 23, 2021
SOURCE: Biogen
Via
3BL Media
Topics
LGBTQ
Exposures
Diversity
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
November 16, 2021
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy...
Via
FinancialNewsMedia
Exposures
COVID-19
Enel X Collaborates With Biogen to Electrify Take-Home Vehicle Fleet in North America
June 29, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Climate Change
Economy
Electric Vehicles
Exposures
Climate
Economy
Electric Vehicles
Kenan Fellows Program and Biogen Foundation Collaborate to Advance Workforce Education
June 23, 2021
SOURCE: Biogen
Via
3BL Media
Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive Year
November 15, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Climate Change
Stocks
Supply Chain
Exposures
COVID-19
Climate
Supply Chain
CEO Climate Alliance to World Leaders: We Support You in Taking Decisive Climate Steps at COP26
November 11, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Emissions
Biogen Launches Supplier Climate Action Program “Energize” With Leading Pharmaceutical Companies
November 04, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Climate Change
Supply Chain
Exposures
Climate
Supply Chain
A Letter From Alphonse Galdes, Ph.D., Head of Pharmaceutical Operations and Technology at Biogen: It's Time for Companies to Act Like the Climate Crisis Is a Health Crisis
November 03, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Climate Change
Death
Emissions
Exposures
Climate
Death
Supply Chain
MIT Collaborates With Biogen on Three-Year, $7 Million Initiative to Address Climate, Health, and Equity
November 01, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Climate Change
Exposures
Climate
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
October 19, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Healthy Climate, Healthy Lives: Advancing Strategic Collaborations
October 13, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Emissions
Healthy Climate, Healthy Lives: Engaging Employees and Suppliers
October 05, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Emissions
Healthy Climate, Healthy Lives: Fossil Fuel Free Operations
September 30, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Emissions
Global Atopic Dermatitis Treatment Market Size Is Projected To Be Worth US$21.80 Billion By 2026
October 12, 2021
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – Atopic Dermatitis is an inflammatory skin disease, and the degree of its severity varies from patient to patient. It usually...
Via
FinancialNewsMedia
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative
September 23, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Emissions
Supply Chain
Exposures
Supply Chain
Alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027
June 24, 2021
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
June 15, 2021
From
Sage Therapeutics, Inc.
Via
Business Wire
Biogen and Eisai Launch Multiple Initiatives to Help Patients With Alzheimer's Disease Access ADUHELM™
June 08, 2021
SOURCE: Biogen
Via
3BL Media
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.